WO2002000708A3 - Vaccin - Google Patents

Vaccin Download PDF

Info

Publication number
WO2002000708A3
WO2002000708A3 PCT/EP2001/007079 EP0107079W WO0200708A3 WO 2002000708 A3 WO2002000708 A3 WO 2002000708A3 EP 0107079 W EP0107079 W EP 0107079W WO 0200708 A3 WO0200708 A3 WO 0200708A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostase
protein
relates
mutants
homologues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/007079
Other languages
English (en)
Other versions
WO2002000708A2 (fr
Inventor
Silva Teresa Elisa Vir Cabezon
Martine Marchand
Y De Bassols Carlota Vinals
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to AU2001285773A priority Critical patent/AU2001285773A1/en
Publication of WO2002000708A2 publication Critical patent/WO2002000708A2/fr
Publication of WO2002000708A3 publication Critical patent/WO2002000708A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouvelles protéines et leur production, à partir de la famille de la prostase. En particulier, l'invention concerne une prostase génétiquement modifiée selon laquelle la protéine a subi une mutation dans son site actif. De tels antigènes peuvent être formulés pour produire des vaccins pour traiter les tumeurs de la prostate. L'invention traite également de procédés pour purifier la protéine de la prostase et ses homologues.
PCT/EP2001/007079 2000-06-27 2001-06-21 Vaccin Ceased WO2002000708A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001285773A AU2001285773A1 (en) 2000-06-27 2001-06-21 Vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015736.2 2000-06-27
GBGB0015736.2A GB0015736D0 (en) 2000-06-27 2000-06-27 Vaccine

Publications (2)

Publication Number Publication Date
WO2002000708A2 WO2002000708A2 (fr) 2002-01-03
WO2002000708A3 true WO2002000708A3 (fr) 2002-05-16

Family

ID=9894505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007079 Ceased WO2002000708A2 (fr) 2000-06-27 2001-06-21 Vaccin

Country Status (4)

Country Link
AR (1) AR033378A1 (fr)
AU (1) AU2001285773A1 (fr)
GB (1) GB0015736D0 (fr)
WO (1) WO2002000708A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786148A (en) * 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
EP0936270A2 (fr) * 1998-02-12 1999-08-18 Basf Aktiengesellschaft Sérine protéase de la prostate
US5955306A (en) * 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
WO2000004149A2 (fr) * 1998-07-14 2000-01-27 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001004143A2 (fr) * 1999-07-13 2001-01-18 Smithkline Beecham Biologicals S.A. Vaccin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955306A (en) * 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
US5786148A (en) * 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
EP0936270A2 (fr) * 1998-02-12 1999-08-18 Basf Aktiengesellschaft Sérine protéase de la prostate
WO2000004149A2 (fr) * 1998-07-14 2000-01-27 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001004143A2 (fr) * 1999-07-13 2001-01-18 Smithkline Beecham Biologicals S.A. Vaccin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NELSON PETER S ET AL: "Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 6, 16 March 1999 (1999-03-16), March 16, 1999, pages 3114 - 3119, XP001038320, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
GB0015736D0 (en) 2000-08-16
AR033378A1 (es) 2003-12-17
WO2002000708A2 (fr) 2002-01-03
AU2001285773A1 (en) 2002-01-08

Similar Documents

Publication Publication Date Title
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
WO2001075087A8 (fr) Variantes de lasubtilisine
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
WO2001083774A3 (fr) Nouvelle forme mutante d'arginine deiminase
AU2002310321A1 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
MY141459A (en) Recombinant anti-idiotypic antibodies
WO2001004143A3 (fr) Vaccin
WO2003022225A3 (fr) Compositions comprenant des melanges de proteines therapeutiques et leurs procedes de preparation
ATE512216T1 (de) Nukleinsäure und dieser entsprechendes, 184p1e2 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
WO2003020875A3 (fr) Polypeptides immunogenes a surfaces exposees aux staphylocoques
WO2002022848A3 (fr) Compositions de melanges de proteines therapeutiques et leurs procedes de production
WO2002044366A3 (fr) Nouvelles proteines humaines specifiques de la retine c7orf9, c12orf7, mpp4 et f379
DE69841995D1 (de) Säugetier milchwachstumsfaktor
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2005049818A3 (fr) Gene
WO2002068668A3 (fr) Compositions et procedes de production de culture cellulaire
WO2002081514A3 (fr) Nouvelle proteine a boite f
WO2001029193A3 (fr) Constructions cellulaires adaptees a l'immunotherapie, leur production et leur utilisation
WO2001075016A3 (fr) Nouveau polypeptide, tyrosinase humaine 16, et polynucleotide codant pour ce polypeptide
WO2001075058A3 (fr) Nouveau polypeptide, aminoacyl-arnt synthetase humaine 15 de type ii, et polynucleotide codant pour ce polypeptide
WO2001075029A3 (fr) Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide
WO2002000831A3 (fr) Nouveau polypeptide, bromodomaine 12, et polynucleotide codant ce polypeptide
WO2001075036A3 (fr) Nouveau polypeptide, immunophiline humaine 14, et polynucleotide codant pour ce polypeptide
WO2001079431A3 (fr) Nouveau polypeptide, proteine humaine d'interaction 15 avec la proteine huntingtine, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP